Carlsmed (CARL) Equity Average (2024 - 2026)

Carlsmed (CARL) has 3 years of Equity Average data on file, last reported at $95.6 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 229.8% year-over-year to $95.6 million; the trailing twelve-month figure through Mar 2026 stood at $95.6 million (up 229.8% YoY), and the FY2025 full-year result was $14.1 million, changed N/A from the prior year.
• Equity Average for Q1 2026 stood at $95.6 million, down from $102.8 million in the prior quarter.
• Across five years, Equity Average topped out at $102.8 million in Q4 2025 and bottomed at -$79.8 million in Q2 2025.
• The 3-year median for Equity Average is -$61.9 million (2024), against an average of -$10.5 million.
• Peak annual rise in Equity Average reached 250.4% in 2025, while the deepest fall reached 119.06% in 2025.
• A 3-year view of Equity Average shows it stood at -$68.3 million in 2024, then jumped by 250.4% to $102.8 million in 2025, then fell by 7.01% to $95.6 million in 2026.
• The last three Equity Average figures came in at $95.6 million (Q1 2026), $102.8 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.

Peer Comparison